TP53与KEAP1突变对局限期及晚期NSCLC生存影响分析
这项回顾性队列研究纳入6297例NSCLC患者,评估TP53与KEAP1突变的预后价值。在1518例手术治疗的局限期(UICC I-IIIA)患者中,截短型TP53突变和KEAP1突变均为独立负性预后因素;在4779例晚期(UICC IIIB-IV)患者中,KEAP1突变仍为负性预后因素,而TP53突变无预后意义。
要点
- 局限期NSCLC中截短型TP53突变和KEAP1突变均为独立负性预后因素
- 晚期NSCLC中KEAP1突变仍为负性预后因素,TP53突变无预后意义
- KEAP1突变合并TP53错义突变的晚期患者总生存优于合并野生型或截短型TP53者
核心结论
- TP53和KEAP1突变对局限期和晚期NSCLC均具有预后价值,其相对风险增加程度与UICC分期增加一个级别相当。
- 建议基于TP53和KEAP1突变状态对局限期和晚期NSCLC进行分子分层,以优化临床决策。
研究设计与样本
- 所有患者均接受分子检测,包括靶向下一代测序panel和原位杂交;主要终点为总生存。
主要发现
- 在1518例手术治疗(UICC I-IIIA)患者中,截短型TP53突变(HR=1.43,95%CI 1.07-1.91,p=0.015)和KEAP1突变(HR=1.68,95%CI 1.24-2.26,p=0.001)为独立负性预后因素,并与较短无病生存相关。
- 在4779例晚期(UICC IIIB-IV)患者中,TP53突变在单变量分析中未预测结局;KEAP1突变仍为负性预后因素(HR=1.40,95%CI 1.23-1.61,p<0.001)。
- KEAP1突变合并TP53错义突变的晚期患者总生存长于KEAP1突变合并TP53野生型或截短型突变的患者。
临床怎么用
- 对局限期和晚期NSCLC患者可考虑检测TP53和KEAP1突变状态,辅助预后分层与临床决策。
- 局限期患者若携带截短型TP53或KEAP1突变,提示预后较差,可能需要更密切随访或强化治疗策略。
- 晚期KEAP1突变患者预后较差,且需注意TP53共突变类型对预后的进一步影响。
局限性
- 本研究为回顾性队列研究,可能存在选择偏倚和混杂因素。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: TP53 and KEAP1 are frequently mutated in NSCLC, but their prognostic value is ambiguous, particularly in localized stage tumors. METHODS: This retrospective cohort study included a total of 6297 patients with NSCLC who were diagnosed between November 1998 and February 2020. The primary end point was overall survival. Patients were diagnosed in a central pathology laboratory as part of the Network Genomic Medicine collaboration, encompassing more than 300 lung cancer-treating oncology centers in Germany. All patients underwent molecular testing, including targeted next-generation panel sequencing and in situ hybridization. RESULTS: A total of 6297 patients with NSCLC were analyzed. In 1518 surgically treated patients (Union for International Cancer Control [UICC] I-IIIA), truncating TP53 mutations and KEAP1 mutations were independent negative prognostic markers in multivariable analysis (hazard ratio [HR]TP53truncating = 1.43, 95% confidence interval [CI]: 1.07-1.91, p = 0.015; HRKEAP1mut = 1.68, 95% CI:1.24-2.26, p = 0.001). Consistently, these mutations were associated with shorter disease-free survival. In 4779 patients with advanced-stage (UICC IIIB-IV) tumors, TP53 mutations did not predict outcome in univariable analysis. In contrast, KEAP1 mutations remained a negative prognostic factor (HRKEAP1mut = 1.40, 95% CI: 1.23-1.61, p < 0.001) in patients with advanced-stage tumors. Furthermore, those with KEAP1-mutant tumors with co-occurring TP53 missense mutations had longer overall survival than those with KEAP1-mutant tumors with wild-type or truncating TP53 mutations. CONCLUSIONS: This study found that TP53 and KEAP1 mutations were prognostic for localized and advanced-stage NSCLC. The increased relative hazard of harboring TP53 or KEAP1 mutations was comparable to an increase in one UICC stage. Our data suggest that molecular stratification on the basis of TP53 and KEAP1 mutation status should be implemented for localized and advanced-stage NSCLC to optimize and modify clinical decision-making.
引用
- Saleh MM, Scheffler M, Merkelbach-Bruse S, et al. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC. J Thorac Oncol. 2021. PMID: 34601169. doi:10.1016/j.jtho.2021.08.764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。